We invest between £0.25 – 10 million
in fast growing businesses
Achilles Therapeutics is designing therapies to target truncal tumour neo-antigens which were first discovered by Cancer Research UK and the NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC) funded scientists at the Francis Crick Institute and UCL Cancer Institute.
Using the latest machine learning techniques and human intelligence to detect astroturfing campaigns at 'Tweet Zero'.
The Bloomsbury AI team joined the London Team of Facebook.
Freeline Therapeutics is a biopharmaceutical company focused on the development of liver-directed gene therapies. The Company will develop and commercialise gene therapies for bleeding and other debilitating disorders.
Hazy automates the process of anonymizing data for companies that hold vast swathes of customer information.
IGEM is an innovative immuno-oncology company targeting cancer with the IgE class of antibodies, which have evolved to kill tissue-dwelling multicellular parasites and exhibit several key features that make it ideal for treating solid tumours
Matr provides one-to-one tutoring services via a proprietary online platform and aims to connect lower cost, higher quality tutoring supply from developing countries to developed economies.
MediaGamma is developing an enterprise grade reinforcement machine learning platform, delivering machine decisions in under 5 milliseconds for a new class of business problems.
MeiraGTx is a vertically integrated, clinical stage gene therapy company. It has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology.
Odin Vision is developing the next generation of AI enabled applications for endoscopic procedures.
Orchard Therapeutics is a biotechnology company dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases. It is a spin-out from the Institute of Child Health (ICH) at UCL.
Leading academics at UCL and University of Bristol with expertise in the fields of computer science, experimental and theoretical physics, and maths have joined forces to create PhaseCraft.
Quell has been established with the aim of developing engineered T regulatory cell therapies. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of solid organ transplant and autoimmune conditions.
We back risk-takers and change-makers. Founders with a vision of the future and the determination to make it happen.
Albion Capital Group LLP is authorised and regulated by the Financial Conduct Authority.
Registered in England No. OC341254 Registered Office: 1 Benjamin St, Farringdon, London, EC1M 5QL. Member of the British Venture Capital Association